Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings (NQ: BPTH )

0.8199 +0.0209 (+2.62%)
Streaming Delayed Price Updated: 12:21 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bio-Path Holdings

< Previous 1 2 Next >
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Publication in Biomedicines
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... 
Via Newsfile
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides Clinical Update and Expansion Plans
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... 
Via Newsfile
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Reports First Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Inc. (NASDAQ: BPTH) Near Top of Volume Charts in Thursday Trading
Via Investor Brand Network
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several Milestones 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... 
Via Newsfile
Bio-Path Holdings Reports Full Year 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.